2. Academic Validation
  3. (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment

(1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment

  • J Med Chem. 2010 Apr 22;53(8):3247-61. doi: 10.1021/jm901893x.
Hiroyuki Kakinuma 1,  Takahiro Oi,  Yuko Hashimoto-Tsuchiya,  Masayuki Arai,  Yasunori Kawakita,  Yoshiki Fukasawa,  Izumi Iida,  Naoko Hagima,  Hiroyuki Takeuchi,  Yukihiro Chino,  Jun Asami,  Lisa Okumura-Kitajima,  Fusayo Io,  Daisuke Yamamoto,  Noriyuki Miyata,  Teisuke Takahashi,  Saeko Uchida,  Koji Yamamoto
Affiliations

Affiliation

  • 1 MedicinalChemistry Laboratories, Taisho Pharmaceutical Co., Ltd. 1-403 Yoshino-cho, Kita-ku, Saitama-shi, Saitama 331-9530, Japan. hiroyuki.kakinuma@po.rd.taisho.co.jp
PMID: 20302302 DOI: 10.1021/jm901893x
Abstract

Derivatives of a novel scaffold, C-phenyl 1-thio-D-glucitol, were prepared and evaluated for sodium-dependent glucose cotransporter (SGLT) 2 and SGLT1 inhibition activities. Optimization of substituents on the aromatic rings afforded five compounds with potent and selective SGLT2 inhibition activities. The compounds were evaluated for in vitro human metabolic stability, human serum protein binding (SPB), and Caco-2 permeability. Of them, (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (3p) exhibited potent SGLT2 inhibition activity (IC(50) = 2.26 nM), with 1650-fold selectivity over SGLT1. Compound 3p showed good metabolic stability toward cryo-preserved human hepatic clearance, lower SPB, and moderate Caco-2 permeability. Since 3p should have acceptable human pharmacokinetics (PK) properties, it could be a clinical candidate for treating type 2 diabetes. We observed that compound 3p exhibits a blood glucose lowering effect, excellent urinary glucose excretion properties, and promising PK profiles in Animals. Phase II clinical trials of 3p (TS-071) are currently ongoing.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z